Jasper Therapeutics Inc Financials
This page shows Jasper Therapeutics Inc (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
R&D-heavy cash consumption is outpacing fresh funding, pushing balance-sheet support from ample to much thinner.
By FY2025, operating cash flow was-$77.2M against only$28.7M of cash, so the business was using more cash in a year than it still held. Liquidity also compressed from FY2023 as the current ratio fell to 2.6x even after new financing, indicating fresh capital is increasingly maintaining operations rather than rebuilding balance-sheet strength.
The expense base is overwhelmingly clinical-development driven: FY2025 R&D was
The balance sheet has moved toward a thin equity cushion, with equity down to
Financial Health Signals
Jasper Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Jasper Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Jasper Therapeutics Inc reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Jasper Therapeutics Inc's EBITDA was -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.6% from the prior year.
Jasper Therapeutics Inc reported -$76 in net income in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Jasper Therapeutics Inc earned -$3.95 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Jasper Therapeutics Inc held $28.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Jasper Therapeutics Inc's ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 115.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Jasper Therapeutics Inc invested $63.1M in research and development in fiscal year 2025. This represents an increase of 13.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
JSPR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Cost of Revenue | N/A | $41.6M+21.5% | $34.3M | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $63.1M+13.0% | $55.8M+7.8% | $51.8M+49.6% | $34.6M+36.2% | $25.4M+60.1% | $15.9M |
| SG&A Expenses | N/A | $20.8M+1.8% | $20.4M+19.6% | $17.1M+3.1% | $16.6M+45.2% | $11.4M+137.8% | $4.8M |
| Operating Income | N/A | -$83.9M-10.0% | -$76.2M-10.7% | -$68.9M-34.5% | -$51.2M-39.0% | -$36.8M-78.1% | -$20.7M |
| Interest Expense | N/A | N/A | N/A | -$246K-113.9% | -$115K-43.8% | -$80K+27.9% | -$111K |
| Income Tax | N/A | N/A | $2K0.0% | $2K | N/A | N/A | $38K |
| Net Income | N/A | -$76+100.0% | -$71.3M-10.5% | -$64.5M-71.2% | -$37.7M-23.0% | -$30.6M+3.3% | -$31.7M |
| EPS (Diluted) | — | -$3.95 | -$4.89+20.9% | -$6.18 | -$10.33 | -$2.69 | N/A |
Not reported in any period shown, so not listed: Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JSPR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $35.8M-55.2% | $79.9M-15.8% | $94.9M+96.2% | $48.4M-48.4% | $93.7M+301.0% | $23.4M |
| Current Assets | $34.6M-54.3% | $75.8M-14.8% | $88.9M+113.1% | $41.7M-52.5% | $87.8M+324.6% | $20.7M |
| Cash & Equivalents | $28.7M-59.9% | $71.6M-17.6% | $86.9M+127.2% | $38.3M-54.8% | $84.7M+327.0% | $19.8M |
| Total Liabilities | $31.6M+73.5% | $18.2M+10.8% | $16.5M+33.0% | $12.4M-48.7% | $24.1M-58.7% | $58.5M |
| Current Liabilities | $13.2M-13.4% | $15.2M+23.1% | $12.4M+75.1% | $7.1M-11.9% | $8.0M+99.9% | $4.0M |
| Total Equity | $4.2M-93.3% | $61.7M-21.4% | $78.4M+118.0% | $36.0M-48.2% | $69.5M+297.9% | -$35.1M |
| Retained Earnings | -$316.7M-31.5% | -$240.9M-42.0% | -$169.6M-61.3% | -$105.1M-55.9% | -$67.5M-83.2% | -$36.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
JSPR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$60.3M | -$77.2M-23.3% | -$62.6M-20.2% | -$52.1M-13.5% | -$45.9M-36.2% | -$33.7M-84.4% | -$18.3M |
| Investing Cash Flow | N/A | $5K+100.9% | -$532K-99.3% | -$267K+53.6% | -$576K+76.3% | -$2.4M-1324.1% | $198K |
| Financing Cash Flow | N/A | $34.2M-28.6% | $47.9M-52.6% | $101.0M+183483.6% | $55K-99.9% | $101.0M+794.6% | $11.3M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JSPR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | 0.0%+115.6pp | -115.6%-33.4pp | -82.2%+22.5pp | -104.7%-60.6pp | -44.1% | N/A |
| Return on Assets | 0.0%+89.2pp | -89.2%-21.3pp | -68.0%+10.0pp | -77.9%-45.2pp | -32.7%+102.9pp | -135.6% |
| Current Ratio | 2.62-2.4x | 4.98-2.2x | 7.19+1.3x | 5.91-5.0x | 10.95+5.8x | 5.16 |
| Debt-to-Equity | 7.62+7.3x | 0.30+0.1x | 0.21-0.1x | 0.340.0x | 0.35 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Jasper Therapeutics Inc Ranks
Frequently Asked Questions
Is Jasper Therapeutics Inc profitable?
No, Jasper Therapeutics Inc (JSPR) reported a net income of -$76 in fiscal year 2025.
What is Jasper Therapeutics Inc's EBITDA?
Jasper Therapeutics Inc (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Jasper Therapeutics Inc's return on equity (ROE)?
Jasper Therapeutics Inc (JSPR) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Jasper Therapeutics Inc's operating cash flow?
Jasper Therapeutics Inc (JSPR) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Jasper Therapeutics Inc's total assets?
Jasper Therapeutics Inc (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Jasper Therapeutics Inc spend on research and development?
Jasper Therapeutics Inc (JSPR) invested $63.1M in research and development during fiscal year 2025.
What is Jasper Therapeutics Inc's current ratio?
Jasper Therapeutics Inc (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.
What is Jasper Therapeutics Inc's debt-to-equity ratio?
Jasper Therapeutics Inc (JSPR) had a debt-to-equity ratio of 7.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Jasper Therapeutics Inc's return on assets (ROA)?
Jasper Therapeutics Inc (JSPR) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jasper Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Jasper Therapeutics Inc (JSPR) had $28.7M in cash against an annual operating cash burn of $77.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Jasper Therapeutics Inc's Piotroski F-Score?
Jasper Therapeutics Inc (JSPR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jasper Therapeutics Inc's earnings high quality?
Jasper Therapeutics Inc (JSPR) reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.